Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF

Journal of Immunology

Volumn 188, Issue 12, 2012, Pages 6389-6398

  Spear, Paul ^a   Barber, Amorette ^a   Rynda Apple, Agnieszka ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CLODRONIC ACID; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOSOME; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CELL INFILTRATION; CELL THERAPY; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; IMMUNOSTIMULATION; MACROPHAGE; MOUSE; NONHUMAN; OVARY TUMOR; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN PRESENTATION; CHIMERA; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84862633912     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103019     Document Type: Article

References (57)

1. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
2. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555. (Pubitemid 35223554)
3. Ostrand-Rosenberg, S. 2008. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 18: 11-18. (Pubitemid 351694442)
4. Hagemann, T., T. Lawrence, I. McNeish, K. A. Charles, H. Kulbe, R. G. Thompson, S. C. Robinson, and F. R. Balkwill. 2008. "Re- educating"tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 205: 1261-1268.
5. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
6. DeNardo, D. G., P. Andreu, and L. M. Coussens. 2010. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 29: 309-316.
7. Biswas, S. K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11: 889-896.
8. Sadelain, M., R. Brentjens, and I. Rivière. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21: 215-223.
9. Sadelain, M., I. Rivière, and R. Brentjens. 2003. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3: 35-45. (Pubitemid 37328885)
10. Barber, A., T. Zhang, and C. L. Sentman. 2008. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J. Immunol. 180: 72-78.
11. Brentjens, R. J., J. B. Latouche, E. Santos, F. Marti, M. C. Gong, C. Lyddane, P. D. King, S. Larson, M. Weiss, I. Rivière, and M. Sadelain. 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes costimulated by CD80 and interleukin-15. Nat. Med. 9: 279-286. (Pubitemid 36362782)
12. Ahmed, N., M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, et al. 2007. Regression of experimental medulloblastoma following transfer of HER2- specific T cells. Cancer Res. 67: 5957-5964. (Pubitemid 46985032)
13. Barber, A., T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67: 5003-5008. (Pubitemid 46910210)
14. Zhang, T., A. Barber, and C. L. Sentman. 2007. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67: 11029-11036. (Pubitemid 350145933)
15. Zhang, T., B. A. Lemoi, and C. L. Sentman. 2005. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551. (Pubitemid 41208564)
16. Zhang, T., A. Barber, and C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933. (Pubitemid 43927148)
17. Barber, A., and C. L. Sentman. 2009. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J. Immunol. 183: 2365-2372.
18. Barber, A., A. Rynda, and C. L. Sentman. 2009. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J. Immunol. 183: 6939-6947.
19. Van Rooijen, N., and A. Sanders. 1994. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 174: 83-93.
20. Tacke, F., D. Alvarez, T. J. Kaplan, C. Jakubzick, R. Spanbroek, J. Llodra, A. Garin, J. Liu, M. Mack, N. van Rooijen, et al. 2007. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117: 185-194. (Pubitemid 46048465)
21. Nibbering, P. H., P. C. Leijh, and R. van Furth. 1987. Quantitative immunocytochemical characterization of mononuclear phagocytes. II. Monocytes and tissue macrophages. Immunology 62: 171-176. (Pubitemid 17140023)
22. Geissmann, F., M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley. 2010. Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
23. Hart, K. M., S. P. Bak, A. Alonso, and B. Berwin. 2009. Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer. Neoplasia 11: 564-573.
24. Scarlett, U. K., J. R. Cubillos-Ruiz, Y. C. Nesbeth, D. G. Martinez, X. Engle, A. T. Gewirtz, C. L. Ahonen, and J. R. Conejo-Garcia. 2009. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 69: 7329-7337.
25. Hagemann, T., J. Wilson, F. Burke, H. Kulbe, N. F. Li, A. Plüddemann, K. Charles, S. Gordon, and F. R. Balkwill. 2006. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 176: 5023-5032.
26. Iellem, A., M. Mariani, R. Lang, H. Recalde, P. Panina-Bordignon, F. Sinigaglia, and D. D'Ambrosio. 2001. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194: 847-853. (Pubitemid 32983019)
27. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon- Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949. (Pubitemid 39273735)
28. Carmeliet, P., Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, et al. 1998. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490. (Pubitemid 28373960)
29. Gabrilovich, D. 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4: 941-952. (Pubitemid 39620069)
30. Watson, G. A., and D. M. Lopez. 1995. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J. Immunol. 155: 3124-3134.
31. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179: 1109-1118.
32. Hamilton, J. A. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8: 533-544. (Pubitemid 351913679)
33. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146. (Pubitemid 37328691)
34. Sica, A., A. Saccani, B. Bottazzi, N. Polentarutti, A. Vecchi, J. van Damme, and A. Mantovani. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164: 762-767. (Pubitemid 30043699)
35. Sica, A., P. Larghi, A. Mancino, L. Rubino, C. Porta, M. G. Totaro, M. Rimoldi, S. K. Biswas, P. Allavena, and A. Mantovani. 2008. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18: 349-355.
36. Grabstein, K. H., D. L. Urdal, R. J. Tushinski, D. Y. Mochizuki, V. L. Price, M. A. Cantrell, S. Gillis, and P. J. Conlon. 1986. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506-508. (Pubitemid 16052365)
37. Spitalny, G. L., and E. A. Havell. 1984. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J. Exp. Med. 159: 1560-1565. (Pubitemid 14123807)
38. Aruga, A., S. Shu, and A. E. Chang. 1995. Tumor-specific granulocyte/ macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol. Immunother. 41: 317-324. (Pubitemid 26008824)
39. Nagoshi, M., P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein. 1998. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J. Immunol. 160: 334-344. (Pubitemid 28116747)
40. Martinez, F. O., L. Helming, and S. Gordon. 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27: 451-483.
41. Hagemann, T., S. K. Biswas, T. Lawrence, A. Sica, and C. E. Lewis. 2009. Regulation of macrophage function in tumors: the multifaceted role of NFkappaB. Blood 113: 3139-3146.
42. Ohmori, Y., and T. A. Hamilton. 2001. Requirement for STAT1 in LPS-induced gene expression in macrophages. J. Leukoc. Biol. 69: 598-604. (Pubitemid 32294845)
43. Vakkila, J., R. A. Demarco, and M. T. Lotze. 2008. Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scand. J. Immunol. 67: 260-269. (Pubitemid 351197169)
44. Coccia, E. M., N. Del Russo, E. Stellacci, U. Testa, G. Marziali, and A. Battistini. 1999. STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. Int. Immunol. 11: 1075-1083. (Pubitemid 29338749)
45. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70: 83-243. (Pubitemid 128678837)
46. Hayes, M. P., J. Wang, and M. A. Norcross. 1995. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 86: 646-650.
47. Sweet, M. J., C. C. Campbell, D. P. Sester, D. Xu, R. C. McDonald, K. J. Stacey, D. A. Hume, and F. Y. Liew. 2002. Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J. Immunol. 168: 392-399. (Pubitemid 34014141)
48. Ma, X., J. M. Chow, G. Gri, G. Carra, F. Gerosa, S. F. Wolf, R. Dzialo, and G. Trinchieri. 1996. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 183: 147-157. (Pubitemid 26028754)
49. Diefenbach, A., H. Schindler, M. Röllinghoff, W. M. Yokoyama, and C. Bogdan. 1999. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 284: 951-955. (Pubitemid 29288431)
50. Weiss, J. M., L. A. Ridnour, T. Back, S. P. Hussain, P. He, A. E. Maciag, L. K. Keefer, W. J. Murphy, C. C. Harris, D. A. Wink, and R. H. Wiltrout. 2010. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 207: 2455-2467.
51. Vicetti Miguel, R. D., T. L. Cherpes, L. J. Watson, and K. C. McKenna. 2010. CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination. J. Immunol. 185: 6706-6718.
52. Hu, X., P. K. Paik, J. Chen, A. Yarilina, L. Kockeritz, T. T. Lu, J. R.Woodgett, and L. B. Ivashkiv. 2006. IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24: 563-574. (Pubitemid 43728157)
53. Curiel, T. J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117: 1167-1174. (Pubitemid 46718401)
54. Saraiva, M., and A. O'Garra. 2010. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10: 170-181.
55. Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R. A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence and growth. Nature 442: 461-465. (Pubitemid 44264796)
56. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178: 6730-6733. (Pubitemid 46847396)
57. Menetrier-Caux, C., G. Montmain, M. C. Dieu, C. Bain, M. C. Favrot, C. Caux, and J. Y. Blay. 1998. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791. (Pubitemid 29005881)